11741 Results

People

  1. Vickers
    Vickers
  2. Offit
    Offit
  3. Robson
    Robson
  4. Horwitz
    Horwitz
  5. Kingham
    Kingham
  6. Panageas
    Panageas
  7. Breitbart
    Breitbart
  8. Halpern
    Halpern
  9. Jarnagin
    Jarnagin
  10. Nelson
    Nelson

Groups

  1. Population Sciences Research Program (11741)
  2. Survivorship Research (5670)
  3. Department of Medicine (5135)
  4. Epidemiology and Biostatistics (4867)
  5. Solid Tumor Oncology Division (3334)
  6. Surgery (2966)
  7. Psychiatry and Behavioral Sciences, Department of (2780)
  8. Biostatistics Service (2339)
  9. GSK Faculty (2009)
  10. Health Outcomes Research Group (1948)
  1. "Population Sciences Research Program"
Formats
  1. Journal Article (7144)
  2. Meeting Abstract (3307)
  3. Book Section (330)
  4. Review (289)
  5. Editorial (253)
  6. Research Letter (116)
  7. Correspondence (111)
  8. Conference Paper (67)
  9. Guidelines (59)
  10. Miscellaneous (41)
  11. Book Whole (24)
Groups
  1. Population Sciences Research Program (11741)
  2. Survivorship Research (5670)
  3. Department of Medicine (5135)
  4. Epidemiology and Biostatistics (4867)
  5. Solid Tumor Oncology Division (3334)
  6. Surgery (2966)

More Groups

People
  1. Andrew Vickers (880)
  2. Kenneth Offit (788)
  3. Mark Robson (676)
  4. Steven Horwitz (645)
  5. T Peter Kingham (609)
  6. Katherine Panageas (512)

More People

Years
  1. 2025 (236)
  2. 2024 (722)
  3. 2023 (821)
  4. 2022 (828)
  5. 2021 (786)
  6. 2020 (738)

More Years

Publications
  1. Journal of Clinical Oncology (1246)
  2. Blood (374)
  3. Psycho-Oncology (347)
  4. Cancer (240)
  5. Cancer Research (234)
  6. Annals of Surgical Oncology (233)

More Publications

Publishers
  1. American Society of Clinical Oncology (1412)
  2. Elsevier Inc. (1128)
  3. Springer (1112)
  4. Elsevier Science, Inc. (816)
  5. Oxford University Press (753)
  6. Wiley Blackwell (614)

More Publishers

Results (11741)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Thirty day resource utilization after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J.; Sauter, C. S.; Duck, E.; Halton, E.; Batlevi, C. W.; Palomba, M. L.; Younes, A.; Geyer, M. B.; Smith, E.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Prevalence and characteristics of caregiver distress one-year after allogeneic hematopoietic cell transplant in an older cohort of patients - A single institution experience
    Meeting Abstract

    Elko, T. A.; Lin, R. J.; Jakubowski, A. A.; Perales, M. A.; Maloy, M. A.; Applebaum, A. J.; Giralt, S. A.
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Palliative care
    Book Section

    Edelstein, A.; Alici, Y.; Breitbart, W.; Chochinov, H. M.
    In Levenson, J. L. (Eds.) American Psychiatric Association Publishing Textbook of Psychosomatic Medicine and Consultation-Liaison Psychiatry. 3rd ed (2019)

    Fulltext@MSK | Save
  • The ECHELON-2 trial: Results of a randomised, double-blind, active-controlled phase 3 study of brentuximab vedotin and CHP (A plus CHP) vs CHOP in the frontline treatment of patients (pts) with CD30(+) peripheral T-cell lymphomas (PTCLs)
    Meeting Abstract

    Trümper, L.; O'Connor, O. A.; Pro, B.; Illidge, T. M.; Advani, R. H.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; Rossi, G.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • An exploratory analysis of brentuximab vedotin plus CHP (A plus CHP) in the frontline treatment of patients with CD30+ peripheral T-cell lymphomas (ECHELON-2): Impact of consolidative stem cell transplant
    Meeting Abstract

    Savage, K. J.; Horwitz, S. M.; Advani, R. H.; Christensen, J. H.; Domingo-Domenech, E.; Rossi, G.; Morschhauser, F.; Alpdogan, O.; Suh, C.; Tobinai, K.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase 2 study of the dual SYK/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma
    Meeting Abstract

    Horwitz, S. M.; Feldman, T. A.; Hess, B. T.; Khodadoust, M. S.; Kim, Y. H.; Munoz, J.; Patel, M. R.; Phillips, T. J.; Smith, S. D.; Smith, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Genomic profiling of mantle cell lymphoma suggests poor-risk profile is present at diagnosis and does not arise by tumor evolution
    Meeting Abstract

    Joffe, E.; Kumar, A.; Zheng, S.; Uppal, M.; Bantilan, K. S.; Atteberry, P.; Straus, D. J.; Palomba, M. L.; Noy, A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Extended mutational profiling by MSK-IMPACT™ identifies mutations predicting thromboembolic risk in patients with solid tumor malignancy
    Meeting Abstract

    Dunbar, A.; Bolton, K.; Devlin, S. M.; Sanchez-Vega, F.; Gao, J.; Mones, J. V.; Wills, J. M.; Kelly, D.; Farina, M.; Kishore, S.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A blizzard of one
    Journal Article

    Breitbart, W.
    Palliative and Supportive Care (2019)

    Fulltext@MSK | Save
  • In memoriam: Ruth McCorkle, PhD, RN, FAPOS, FAAN (1940-2019)
    Miscellaneous

    Applebaum, A. J.
    Palliative and Supportive Care (2019)

    Fulltext@MSK | Save